Hematology testing: a cornerstone in modern diagnostics
Clinical diagnostics form the backbone of healthcare, guiding medical decisions across every stage of care. Among these, hematology testing stands out as one of the most widely requested analyses — used for initial patient assessments, disease monitoring, and treatment evaluation.
Since the launch of the first automated hematology analyzers in the 1950s, the method has become a global standard in diagnostic laboratories. Hematology analysis remains one of the most accessible and cost-effective tools for identifying a wide range of conditions, including anemia, infections, coagulation disorders, and blood cancers.
Global market trends and technological shifts
The demand for hematology testing continues to rise, driven by the aging population and increased healthcare investments in emerging markets.
While hematology testing was traditionally centralized in large laboratories, technological innovation has enabled manufacturers to produce compact devices that deliver laboratory-quality CBC results directly in primary care settings. These systems connect seamlessly with Laboratory Information Systems (LIS), improving workflow and reducing turnaround time for diagnostics.
Decentralized hematology testing now plays a major role in global healthcare, with the market projected to reach 821 million USD by 2024. Improved cost-efficiency of benchtop analyzers and the acceleration of point-of-care testing during the COVID-19 pandemic have further fueled this growth.
Why on-site hematology testing matters
Centralized testing offers economies of scale, but near-patient testing provides crucial advantages for both patients and clinicians:
Faster turnaround times for urgent cases
Convenience, no need to travel or transfer samples
Reduced pre-analytical risk, such as coagulation during transport
Low-cost on-site CBC testing supports disease monitoring, oncology assessments, and screening of blood donors. Frequent testing is especially beneficial for conditions affecting blood cells, such as dengue, malaria, or chemotherapy monitoring.
What defines a reliable on-site analyzer
For decentralized healthcare environments — from doctor’s offices to rural clinics — analyzers must combine accuracy, simplicity, and resilience.
Key design requirements include:
Compact footprint for space-limited settings
Ease of use for non-laboratory staff
Fast results from small sample volumes
Stable reagents that store at room temperature
Reliable performance with minimal maintenance
A robust design ensures that even remote facilities can deliver CBC results in under a minute, supporting patient-centric care and rapid clinical decisions.
Technologies powering the future of hematology testing
While electrical impedance remains the core principle of blood cell counting, new technologies continue to refine hematology analysis.
In the 1980s, optical flow cytometry revolutionized white blood cell differentiation. Today, AI-assisted digital imaging and optical microscopy automate blood smear evaluations, detecting cell morphologies that are difficult for traditional systems to identify.
Connectivity now plays a critical role — enabling data sharing, remote diagnostics, and cloud-based instrument monitoring. These advancements support the trend toward decentralized and patient-centered testing.
Partnering for accessible hematology worldwide
“Since partnering with Boule for the distribution of Medonic systems in our country, we’ve captured a major share of the market — especially in primary care centers. Boule analyzers are recognized for offering the best value for money.”
— Yodely Tavares, Managing Director, Cruz Ayala, Dominican Republic“Clients who once hesitated about analyzer reliability now process double their daily samples. The growing interest in advanced 5-part analyzers and remote diagnostics shows how fast the market is evolving.”
— Máximo Cruz Ayala, CEO, Cruz Ayala
Boule’s vision: innovation rooted in reliability
Since the 1950s, Boule Diagnostics has supported hematology laboratories across the world, combining robust design, space-efficient solutions, and fingerstick sampling technology to make testing faster and more accessible.
Today, Boule analyzers are purpose-built for decentralized healthcare, delivering complete blood counts and WBC differentials in just one minute.
Emerging technologies such as AI, expanded parameters, and cloud-based data access will continue to shape the next generation of hematology testing.
Learn more
Read more about the history of Boule Diagnostics here.
References
- Report: Hematology and Coagulation Markets, Kalorama, May 2020
- Agarwal et al. How SARS-CoV-2 Will Catalyze Decentralized Testing. www.healthadvancesblog.com Apr 2020 (accessed 27 Feb 2021).
- Whelan, C. 17 benefits of telemedicine for doctors and patients. www.healthline.com Nov 9 2020 (accessed 27 Dec 2020).
- Hagve, T-A. Fra mikroskop til flowcelle. Klinisk Biokemi i Norden 2, 8–17 (2007).